PYDERIN, a skincare brand exclusively for hospitals and clinics, announced the official launch of its regenerative cream 'REJUVUSTER' (pictured), featuring PDRN (Polydeoxyribonucleotide) as its main ingredient, through pharmacy distribution channels. PYDERIN, which has primarily focused on medical institution channels, plans to expand its consumer reach by concurrently selling through pharmacies starting with this launch.
PDRN is a DNA-derived ingredient extracted from salmon testes, known to aid in the recovery and regeneration of damaged skin tissue. Accordingly, it is gaining attention in the skin recovery category for its potential to help improve overall skin concerns such as whitening, moisturizing, and pore management.
The domestic regenerative cream market is rapidly expanding, driven by the high growth of PDRN-based 'REJUVINEX', and competition is fierce with various products from strong players in the pharmacy market such as 'Madecassol Gel', 'EGF Regenerative Cream', and 'Acnon Cream'. Amidst this, PYDERIN's 'REJUVUSTER' stated that it has proven skin regeneration and wrinkle improvement effects through clinical trials, and has strengthened its credibility by emphasizing 99% purity, 97 kDa ultra-low molecular weight, and a content of 10,000 ppm.
A PYDERIN official stated, "REJUVUSTER is a product that integrates the know-how accumulated in hospital and clinic channels into pharmacy distribution," adding, "Through a PDRN-based high-purity, high-content, low-molecular-weight design, we aim to provide consumers with a skin condition recovery experience they can quickly feel."
PYDERIN plans to expand its supply network, focusing on major pharmacies nationwide, and concurrently run consumer experience campaigns and HCP (healthcare professional) education programs to broaden options in the regenerative cream category and further clarify the competitive landscape.
Source: Medisobiza News (http://www.medisobizanews.com)
Reporter Park Chan-young admin@medisobizanews.com
